AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMURON LTD

0.028

0.000

Volume:- -

Turnover:- -

Market Cap:9.15M

PE:-1.22

High:0.028

Open:0.028

Low:0.028

Close:0.028

52wk High:0.098

52wk Low:0.026

Shares:326.65M

Float Shares:265.37M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.023

EPS(LYR):-0.023

ROE:-39.68%

ROA:-21.93%

PB:0.70

PE(LYR):-1.24

Loading ...

Overview Company News Filings

Immuron Ltd - Research Agreement Funded by U.S. Department of Defense Subaward

THOMSON REUTERS

Immuron Ltd - to Produce Two Hyper-Immune Bovine Colostrum Products

THOMSON REUTERS

BRIEF-Immuron Receives US Department Of Defense Award For Oral Therapeutics Development

BUZZ-Australia's Immuron hits near 1-month high on US Defense-funded research

Immuron Ltd-U.S. Department of Defense Award & Clinical Trial Update

THOMSON REUTERS

Immuron Limited Announces Director Interest Disclosure Availability

Immuron Says IMM-529 IND Approved By FDA

Immuron Ltd-CEO Address

THOMSON REUTERS

Immuron Limited Announces US$8.5 Million Share Placement to US Investors

Immuron Ltd-Proposed Issue of Securities - Imc

THOMSON REUTERS

BRIEF-Immuron Says IMM-529 IND Approved By FDA

FDA Approves IND Application for Immuron’s IMM-529 to Treat C. difficile Infection

Immuron Ltd - Plans Phase 2 Trial for Imm-529 in First Half of 2026

THOMSON REUTERS

Immuron Ltd - Imm-529 Ind Approved by FDA

THOMSON REUTERS

BRIEF-Immuron Announces Clinical Trial Update

Immuron's IMM-529 IND Under Active FDA Review

Immuron Ltd - Travelan P2TD Study Data Delayed to End of November

THOMSON REUTERS

Immuron Ltd - Imm-529 Ind Under Review, FDA Request Addressed

THOMSON REUTERS

Immuron Ltd-Clinical Trial Update

THOMSON REUTERS

Indigenously Designed and Manufactured Laptops by Vyonix Launched at IMC 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMC.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","market":"AU","secType":"STK","nameCN":"IMMURON LTD","latestPrice":0.028,"timestamp":1775088531739,"preClose":0.028,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"IMMURON LTD","floatShares":265374293,"shares":326653609,"eps":-0.023,"marketStatus":"Trading","change":0,"latestTime":"04-02 12:04:53 AEDT","open":0.028,"high":0.028,"low":0.028,"amount":0,"amplitude":0,"askPrice":0.028,"askSize":64000,"bidPrice":0.026,"bidSize":343500,"shortable":3,"etf":0,"ttmEps":-0.023,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775106000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.028,"openAndCloseTimeList":[[1775084400000,1775106000000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMC.AU","preClose":0.03,"auctionPrice":0.03,"auctionVolume":4424,"auction":3,"marketStatus":"盘后竞价","timestamp":1774501204664}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","floatShares":265374293,"roa":"-21.93%","roe":"-39.68%","lyrEps":-0.022586,"shares":326653609,"dividePrice":0,"high":0.028,"amplitude":0,"preClose":0.028,"low":0.028,"week52Low":0.026,"pbRate":"0.70","psRate":"1.22","week52High":0.098,"institutionHeld":0,"latestPrice":0.028,"committee":0.68589,"eps":-0.023,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.023,"open":0.028,"prevYearClose":0.036,"prevWeekClose":0.033,"prevMonthClose":0.028,"prevQuarterClose":0.028,"fiveDayClose":0.033,"twentyDayClose":0.028,"sixtyDayClose":0.035},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-02-28","symbol":"IMC.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1677502800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMC.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588401027","title":"Immuron Ltd - Research Agreement Funded by U.S. Department of Defense Subaward","url":"https://stock-news.laohu8.com/highlight/detail?id=2588401027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588401027?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:00","pubTimestamp":1764759600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA9PVPSY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588010272","title":"Immuron Ltd - to Produce Two Hyper-Immune Bovine Colostrum Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2588010272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588010272?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:00","pubTimestamp":1764759600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA9PVPSY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588097947","title":"BRIEF-Immuron Receives US Department Of Defense Award For Oral Therapeutics Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2588097947","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588097947?lang=en_us&edition=fundamental","pubTime":"2025-12-03 14:01","pubTimestamp":1764741675,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Receives US Department Of Defense Award For Oral Therapeutics DevelopmentDec 3  - Immuron Ltd IMC.AX:U.S. DEPARTMENT OF DEFENSE AWARD & CLINICAL TRIAL UPDATERECEIVES US DEPARTMENT OF DEFENSE AWARD FOR ORAL THERAPEUTICS DEVELOPMENTFurther company coverage: IMC.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUE8PBT9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588091452","title":"BUZZ-Australia's Immuron hits near 1-month high on US Defense-funded research","url":"https://stock-news.laohu8.com/highlight/detail?id=2588091452","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588091452?lang=en_us&edition=fundamental","pubTime":"2025-12-03 12:02","pubTimestamp":1764734555,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immuron hits near 1-month high on US Defense-funded research** Shares of Australia's Immuron IMC.AX rise as much as 12.1% to A$0.074, their highest since November 5** Biopharmaceutica","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X908E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588093123","title":"Immuron Ltd-U.S. Department of Defense Award & Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2588093123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588093123?lang=en_us&edition=fundamental","pubTime":"2025-12-03 09:40","pubTimestamp":1764726029,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUE8PBT9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585259921","title":"Immuron Limited Announces Director Interest Disclosure Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2585259921","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585259921?lang=en_us&edition=fundamental","pubTime":"2025-11-22 04:51","pubTimestamp":1763758275,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL5ySGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immuron Limited Announces Director Interest Disclosure Availability","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584926851","title":"Immuron Says IMM-529 IND Approved By FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926851","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926851?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:38","pubTimestamp":1763570297,"startTime":"0","endTime":"0","summary":"Nov 5 (Reuters) - Immuron Ltd ::*IMM-529 IND APPROVED BY FDA*Further company coverage: IMC.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 05-NOV-202511:12:18.977 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD88gNP1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582897033","title":"Immuron Ltd-CEO Address","url":"https://stock-news.laohu8.com/highlight/detail?id=2582897033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582897033?lang=en_us&edition=fundamental","pubTime":"2025-11-11 07:37","pubTimestamp":1762817844,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUE7FMF2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581678190","title":"Immuron Limited Announces US$8.5 Million Share Placement to US Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581678190","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581678190?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:11","pubTimestamp":1762431096,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced a proposed issue of up to 8,495,080 ordinary fully paid shares  to US investors through its US At-The-Market  facility managed by H.C. Wainwright & Co. The facility is described as low fee and no discount. The company stated that there will be no change to its dividend or distribution policy as a result of this share issuance. The shares are expected to be issued on July 11, 2025, and the company has confirmed compliance with secondary sale provisions under Australian law through the publication of a cleansing notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieva","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL48sgF2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581818250","title":"Immuron Ltd-Proposed Issue of Securities - Imc","url":"https://stock-news.laohu8.com/highlight/detail?id=2581818250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581818250?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:06","pubTimestamp":1762387580,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8RNV3Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581251697","title":"BRIEF-Immuron Says IMM-529 IND Approved By FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2581251697","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581251697?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:25","pubTimestamp":1762341936,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Says IMM-529 IND Approved By FDANov 5 (Reuters) - Immuron Ltd IMC.AX:IMM-529 IND APPROVED BY FDAFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WG1TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581272353","title":"FDA Approves IND Application for Immuron’s IMM-529 to Treat C. difficile Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2581272353","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581272353?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:00","pubTimestamp":1762340421,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced that the U.S. Food and Drug Administration  has approved its Investigational New Drug  application for IMM-529, allowing the company to proceed with a Phase 2 clinical trial targeting Clostridioides difficile infection . The IND approval enables Immuron to begin clinical development of IMM-529, which is designed to prevent and treat CDI, including recurrent cases. IMM-529 utilizes antibodies derived from hyperimmune bovine colostrum and has demonstrated promising results in pre-clinical models for prevention, protection against recurrence, and treatment of CDI. The Phase 2 trial is expected to start in the first half of 2026. No other organizations were mentioned as recipients of the regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL8TFDFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK7067","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK7508","LU2095319765.USD","NDAQ","BK4588","BK4585","IMC.AU","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581872349","title":"Immuron Ltd - Plans Phase 2 Trial for Imm-529 in First Half of  2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581872349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581872349?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:00","pubTimestamp":1762340400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUACGMXN0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581446716","title":"Immuron Ltd - Imm-529 Ind Approved by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2581446716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581446716?lang=en_us&edition=fundamental","pubTime":"2025-11-05 12:05","pubTimestamp":1762315530,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WG1TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579454765","title":"BRIEF-Immuron Announces Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2579454765","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579454765?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:00","pubTimestamp":1761904849,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Announces Clinical Trial UpdateOct 31 (Reuters) - Immuron Ltd IMC.AX:IMMURON ANNOUNCES CLINICAL TRIAL UPDATEIMMURON LTD - TRAVELAN P2TD STUDY DATA DELAYED TO END OF NOVEMBERIMMURON LTD -","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUABFY7JM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579454792","title":"Immuron's IMM-529 IND Under Active FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2579454792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579454792?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:00","pubTimestamp":1761904816,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced that its Investigational New Drug  application for IMM-529, aimed at preventing or treating Clostridioides difficile infection, is currently under active review by the U.S. Food and Drug Administration . The FDA has formally acknowledged receipt of the IND and assigned a biologic product name and IND number. Following a recent request from the FDA for additional clinical information, Immuron submitted a comprehensive response and made minor updates to the clinical protocol to address the agency's recommendations. The IND remains under review ahead of the FDA's 30-day decision date. No new grant or funding announcement was made.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the or","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL68bcPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD","LU0314104364.USD","LU2210150020.SGD","BK7067","NDAQ","BK7508","IMC.AU","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579454248","title":"Immuron Ltd - Travelan P2TD Study Data Delayed to End of November","url":"https://stock-news.laohu8.com/highlight/detail?id=2579454248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579454248?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:00","pubTimestamp":1761904800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUABFY7JM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579454243","title":"Immuron Ltd - Imm-529 Ind Under Review, FDA Request Addressed","url":"https://stock-news.laohu8.com/highlight/detail?id=2579454243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579454243?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:00","pubTimestamp":1761904800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUABFY7JM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579109347","title":"Immuron Ltd-Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2579109347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579109347?lang=en_us&edition=fundamental","pubTime":"2025-10-31 06:23","pubTimestamp":1761863038,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUEB2JMCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578432661","title":"Indigenously Designed and Manufactured Laptops by Vyonix Launched at IMC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2578432661","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578432661?lang=en_us&edition=fundamental","pubTime":"2025-10-27 09:00","pubTimestamp":1761526800,"startTime":"0","endTime":"0","summary":"GURUGRAM, India, Oct. 27, 2025 /PRNewswire/ -- India's 1st indigenously designed and manufactured Laptops, were launched at the India Mobile Congress  2025 by Vyonix. Designed, engineered, and manufactured entirely in India for Vyonix by VVDN Technologies, a global provider of software, product engineering, electronics manufacturing services and solutions, these Laptops underscores VVDN's commitment to innovation, quality, and the nation's \"Design & Make in India\" vision.Amit Saharan, Sr. Vice President, Sales, VVDN Technologies:  \"Vyonix Laptops are a testament to VVDN's engineering excellence and commitment to enabling India's electronics ecosystem. These laptops aim to empower partners to bring cutting-edge, indigenously built laptops to market with speed and confidence. Vyonix combines the best of design, performance, and reliability - truly redefining the computing experience.\"Vyonix Laptops can also be available to OEMs for white labelling, enabling partners to bring locally manu","market":"other","thumbnail":"https://mma.prnewswire.com/media/2804940/Vyonix.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2804940/Vyonix.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/indigenously-designed-and-manufactured-laptops-by-vyonix-launched-at-imc-2025-302594313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNDmain","BK7067","BK7508","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":62,"code":"91000000","status":"200"}]}}